Hepatitis Associated Aplastic Anaemia: Epidemiology and Treatment Results obtained in Europe. A Report of The EBMT Aplastic Anemia Working Party
Résumé
Aim: assess the epidemiology of Hepatitis-Associated Aplasia (HAA) and compare treatment outcome of HAA with non-HAA patients. Patients. We evaluated 3916 aplastic anemia patients reported to the European Registry between 1990 and 2007. Year, month ,season of diagnosis, type and outcome of first line therapy were analyzed . Results. Prevalence of HAA (n=214) in Europe was 5%. HAA patients,compared to non-HAA were younger (15 vs 20 years, p<0.001), with a male prevalence (68% vs 58% p=0.002), and were treated earlier after diagnosis (46 vs 62 days; p<0.001). No significant differences were found according to the year or month of diagnosis. No geographic clusters could be identified. Actuarial survival at 10 years after first line immunosuppression was 69% , and did not differ according to etiology . The 10 year actuarial survival after transplantation was 70%, and was comparable in HAA and non-HAA patients, when stratified for age and donor type. In a multivariate COX analysis, increasing age and delayed treatment were significant negative indicators for survival. Conclusions. The incidence of HAA is 5% and is evenly distributed over time and geographic areas in Europe. Treatment outcome , and predictive variables , are comparable in patients with or without HAA.
Fichier principal
PEER_stage2_10.1111%2Fj.1365-2141.2010.08194.x.pdf (225.63 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...